Lung Cancer | Clinical

Overcoming Resistance to ICI Therapy With Ramucirumab and Pembrolizumab in Advanced NSCLC

June 27, 2022

In an interview with Targeted Oncology™, Karen L. Reckamp, MD, discussed that limited options for patients with advanced NSCLC who are resistant to immune checkpoint inhibitor therapy. Reckamp also discusses how Lung-MAP research might play a hand in bringing new therapies in the future.

Chemoimmunotherapy Shows 3-Year Survival Benefit for Advanced NSCLC

June 22, 2022

During a live virtual event, Adam J. Schoenfeld, MD, discussed the updated 3-year results of the CheckMate 9LA trial of nivolumab, ipilimumab, and 2 cycles of chemotherapy for patients with advanced non–small cell lung cancer.

Part 2: Considerations for Using Adjuvant Chemotherapy and Osimertinib in NSCLC

June 13, 2022

During a live virtual event, Aaron E. Lisberg, MD, discussed the use of adjuvant chemotherapy regimens and the significance of the ADAURA trial of osimertinib for patients with early-stage non–small cell lung cancer with certain EGFR mutations.

FDA Accepts sBLA for Pembrolizumab in Stage IB, II, or III NSCLC

June 13, 2022

A new supplemental biologics license application has been accepted by the FDA for pembrolizumab as treatment of patients with 1B (≥4 centimeters), 2, or 3 non-small cell lung cancer after complete surgical resection.

KEYNOTE-799 Results Reveal Durable Responses in Previously Untreated Stage III NSCLC

June 09, 2022

In patients with previously untreated, locally advanced stage III non–small cell lung cancer, continued benefit from pembrolizumab with concurrent chemoradiation followed by additional pembrolizumab was observed after more than 2 years of follow-up.